GlobeNewswire
-
CDT Notes Sarborg’s Sale of Cryptocurrency Trading Agent
19/11/2026 -
EBI Reaches Key Milestone with First Patient Enrolled in Phase III EasyBoost Trial of EA-230, a Potential First-in-Class Medicine to Accelerate Recovery After Cardiac Surgery
19/11/2026 -
Zymeworks Announces Participation in Upcoming Investor Conferences
19/11/2026 -
Codexis to Participate in Piper Sandler 38th Annual Healthcare Conference
19/11/2026 -
HUTCHMED Announces China NMPA Approval of SYVIK® (sovleplenib) for the Treatment of Primary Immune Thrombocytopenia and Warm Antibody Autoimmune Hemolytic Anemia
19/11/2026 -
A Race Against Blindness Brings Back “Miles, Magic & Mochas” Fundraiser for the Holiday Season
19/11/2026 -
Asgard Therapeutics awarded €2.5m EIC Accelerator grant to advance lead program AT-108 toward the clinic
19/11/2026 -
ALK presents new data at FAAM-EUROBAT-ISMA 2026: Data from a comparative study using adrenaline trainer devices suggests EURneffy® nasal adrenaline spray is more suitable for public places than an adrenaline auto-injector
19/11/2026 -
AVA6207 Overcomes Topoisomerase I Inhibitor Resistance In Vitro and In Vivo with Robust and Tumor-Selective Release of Dual Exatecan and ATR Inhibitor Payloads
19/11/2026 -
DISCO Pharmaceuticals Announces Strategic Collaboration with AbbVie to Advance Next-Generation AND-Gated Bispecific Therapeutics for Solid Tumors
19/11/2026 -
Scancell Provides Corporate and Clinical Update
19/11/2026 -
Interim Results for the Third Quarter of 2026 - BioPorto reports continued NGAL growth and advances the U.S. Adult Validation Study
19/11/2026 -
Press Release: Sanofi’s next-generation rabies vaccine, VaxRabeo, approved in the EU for all ages
19/11/2026 -
Communiqué de presse : VaxRabeo, le vaccin contre la rage de nouvelle génération de Sanofi, approuvé dans l’UE pour tous les âges
19/11/2026 -
Novartis projects +5% cc¹ sales CAGR through 2031 and sustained mid-single-digit growth over the long term
19/11/2026 -
Fangzhou and Baiyunshan Pharmaceutical Launch AI-Powered Chronic Disease Management Initiative
19/11/2026 -
SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public Offering
19/11/2026 -
Immutep Reports Encouraging Disease-Free Survival from EFTISARC-NEO Phase II Trial in Soft Tissue Sarcoma
19/11/2026 -
HUTCHMED Highlights HMPL-A830 Pre-Clinical Data Presented at the 38th EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics
19/11/2026
Pages